Abstract
BACKGROUND: Patients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can currently be offered effective means of prevention, such as implantable cardioverter-defibrillators (ICD). However, predictors of SCD able to identify those patients who are at higher risk are still lacking. Whether C-reactive protein (CRP), a serum inflammatory marker with established prognostic accuracy after MI, can also be a predictor of SCD is unclear. METHODS: The CAMI GUIDE study is designed to evaluate the prognostic role of CRP in patients undergoing ICD implantation after MI according to MADIT II criteria (i.e. left ventricular ejection fraction ≤ 30%). CAMI GUIDE is a prospective observational study aimed at assessing the role of CRP in the risk-stratification of SCD after MI. CRP will be measured on the basis of a pre-specified cut-off value of 3 mg/l, before and 1 month after ICD implantation; clinical follow-up will last 24 months. The primary endpoint is the combined rate of SCD or fast ventricular tachycardia/ventricular fibrillation. Secondary endpoints will be total mortality, death due to acute coronary syndromes, death from pump failure, non-fatal MI, coronary revascularization, hospitalization for congestive heart failure or unstable angina and inappropriate ICD shocks. Twenty-four Italian centers will participate in enrolment of the 290 patients planned according to power analysis. CONCLUSIONS: The CAMI GUIDE study will assess the predictive role of CRP in SCD in patients with previous MI undergoing ICD implantation. Its results will improve risk stratification, thereby enabling better-tailored and more cost-effective therapies to be undertaken in those patients whose need is greatest.
| Original language | English |
|---|---|
| Pages (from-to) | 293-299 |
| Number of pages | 7 |
| Journal | Journal of Cardiovascular Medicine |
| Volume | 8 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2007 |
Fingerprint
Keywords
- C-reactive protein
- Myocardial infarction
- Risk stratification
- Sudden cardiac death
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators : Design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study. / Bellocci, Fulvio; Biasucci, Luigi M.; Gensini, Gian Franco; Padeletti, Luigi; Raviele, Antonio; Santini, Massimo; Giubilato, Giovanna; Landolina, Maurizio; Biondi-Zoccai, Giuseppe; Raciti, Giovanni; Sassara, Massimo; Castro, Antonello; Kheir, Antoine; Crea, Filippo.
In: Journal of Cardiovascular Medicine, Vol. 8, No. 4, 04.2007, p. 293-299.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Prognostic role of post-infarction C-reactive protein in patients undergoing implantation of cardioverter-defibrillators
T2 - Design of the C-reactive protein Assessment after Myocardial Infarction to GUide Implantation of DEfibrillator (CAMI GUIDE) study
AU - Bellocci, Fulvio
AU - Biasucci, Luigi M.
AU - Gensini, Gian Franco
AU - Padeletti, Luigi
AU - Raviele, Antonio
AU - Santini, Massimo
AU - Giubilato, Giovanna
AU - Landolina, Maurizio
AU - Biondi-Zoccai, Giuseppe
AU - Raciti, Giovanni
AU - Sassara, Massimo
AU - Castro, Antonello
AU - Kheir, Antoine
AU - Crea, Filippo
PY - 2007/4
Y1 - 2007/4
N2 - BACKGROUND: Patients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can currently be offered effective means of prevention, such as implantable cardioverter-defibrillators (ICD). However, predictors of SCD able to identify those patients who are at higher risk are still lacking. Whether C-reactive protein (CRP), a serum inflammatory marker with established prognostic accuracy after MI, can also be a predictor of SCD is unclear. METHODS: The CAMI GUIDE study is designed to evaluate the prognostic role of CRP in patients undergoing ICD implantation after MI according to MADIT II criteria (i.e. left ventricular ejection fraction ≤ 30%). CAMI GUIDE is a prospective observational study aimed at assessing the role of CRP in the risk-stratification of SCD after MI. CRP will be measured on the basis of a pre-specified cut-off value of 3 mg/l, before and 1 month after ICD implantation; clinical follow-up will last 24 months. The primary endpoint is the combined rate of SCD or fast ventricular tachycardia/ventricular fibrillation. Secondary endpoints will be total mortality, death due to acute coronary syndromes, death from pump failure, non-fatal MI, coronary revascularization, hospitalization for congestive heart failure or unstable angina and inappropriate ICD shocks. Twenty-four Italian centers will participate in enrolment of the 290 patients planned according to power analysis. CONCLUSIONS: The CAMI GUIDE study will assess the predictive role of CRP in SCD in patients with previous MI undergoing ICD implantation. Its results will improve risk stratification, thereby enabling better-tailored and more cost-effective therapies to be undertaken in those patients whose need is greatest.
AB - BACKGROUND: Patients at risk of sudden cardiac death (SCD) after myocardial infarction (MI) can currently be offered effective means of prevention, such as implantable cardioverter-defibrillators (ICD). However, predictors of SCD able to identify those patients who are at higher risk are still lacking. Whether C-reactive protein (CRP), a serum inflammatory marker with established prognostic accuracy after MI, can also be a predictor of SCD is unclear. METHODS: The CAMI GUIDE study is designed to evaluate the prognostic role of CRP in patients undergoing ICD implantation after MI according to MADIT II criteria (i.e. left ventricular ejection fraction ≤ 30%). CAMI GUIDE is a prospective observational study aimed at assessing the role of CRP in the risk-stratification of SCD after MI. CRP will be measured on the basis of a pre-specified cut-off value of 3 mg/l, before and 1 month after ICD implantation; clinical follow-up will last 24 months. The primary endpoint is the combined rate of SCD or fast ventricular tachycardia/ventricular fibrillation. Secondary endpoints will be total mortality, death due to acute coronary syndromes, death from pump failure, non-fatal MI, coronary revascularization, hospitalization for congestive heart failure or unstable angina and inappropriate ICD shocks. Twenty-four Italian centers will participate in enrolment of the 290 patients planned according to power analysis. CONCLUSIONS: The CAMI GUIDE study will assess the predictive role of CRP in SCD in patients with previous MI undergoing ICD implantation. Its results will improve risk stratification, thereby enabling better-tailored and more cost-effective therapies to be undertaken in those patients whose need is greatest.
KW - C-reactive protein
KW - Myocardial infarction
KW - Risk stratification
KW - Sudden cardiac death
UR - http://www.scopus.com/inward/record.url?scp=34247169004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247169004&partnerID=8YFLogxK
U2 - 10.2459/01.JCM.0000263496.52656.95
DO - 10.2459/01.JCM.0000263496.52656.95
M3 - Article
C2 - 17413310
AN - SCOPUS:34247169004
VL - 8
SP - 293
EP - 299
JO - Journal of Cardiovascular Medicine
JF - Journal of Cardiovascular Medicine
SN - 1558-2027
IS - 4
ER -